Valirx (VAL)

 

VAL Share PerformanceMore

52 week high11.4900 04/10/16
52 week low1.7000 22/08/17
52 week change -6.3930 (-78.68%)
4 week volume17,376,300 27/07/17

Media for (VAL)

Presenter: Suzanne Dilly
15/06/2017
Presenter: Dr Satu Vainikka
08/05/2017

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Convertible Loan Facility

RNS Number: 7140N ValiRx PLC 11 August 2017 Va li R x P lc ("ValiRx" or "the Company" or "the Group") Convertible Loan Facility London, UK., 11 August 2017: ValiRx Plc (AIM: VAL), a clinical stage biotechnology company, announces that it has drawn down US$400,000 of the third tranche of its Convertible Loan Facility (announced on 02 September 2016) wi...

Conversion of Loan Note

RNS Number: 8102M ValiRx PLC 02 August 2017 ValiRx Plc ("ValiRx" or the "Company") Loan Note Conversion and Issue of Equity London, UK ., 2 August 2017: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines towards commercialisation...

ValiRx signs first product licensing agreement

ValiRx (VAL), a clinical stage biotechnology company, has signed a licensing agreement with Mystic Pharmaceuticals in B...

Licencing Agreement

RNS Number: 3478M ValiRx PLC 28 July 2017 ValiRx Plc ("ValiRx" or the "Company") VALIRX AND MYSTIC PHARMACEUTICALS SIGN LICENCE AGREEMENT London, UK ., 28 July 2017: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company , is pleased to announce that ValiRx has signed a licensing agreement with Mystic Pharmaceuticals L...

Formation of & Appointments to an Advisory Board

RNS Number: 8054I ValiRx PLC 22 June 2017 ValiRx Plc ("ValiRx" or the "Company") FORMATION OF & APPOINTMENTS TO AN ADVISORY BOARD London, UK ., 22 June 2017: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company , is pleased to announce the formation of an Advisory Board ("AB") and that the following individuals have agre...

ValiSeek Development Update - Recruitment Closes

RNS Number: 1252I ValiRx PLC 15 June 2017 ValiRx Plc ("ValiRx" or "the Company") ValiSeek Clinical Development Update Recruitment closes London, UK ., 15 June 2017: ValiRx Plc (AIM: VAL), the clinical stage biotechnology company , is pleased to provide an update on the clinical development of ValiSeek Limited ("ValiSeek"), the joint venture ("JV") between...

ValiRx - ValiSeek Clinical Development Update

ValiRx updates on Yorkville CLN Conversion

ValiRx has announced the conversion of the first tranche of the YA Global Master SPV Convertible Loan Facility (CLN). ...

Fundamental DataMore

EPS-8.54
Dividend yield0 %

Equity Research (VAL)

hardman & co
ValiRx plc
31/05/2017
ValiRx is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment of cancer, associated biomarkers and companion diagnostics. The company’s two leading...
edison investment research
ValiRx plc
20/01/2015
V22 is an enterprise that showcases the wealth of talent in contemporary art. It has built a broad portfolio of around 150 artworks of living artists from around the world, paying in a mix of cash...

Latest discussion posts More

Users' HoldingsMore

Users who hold Valirx also hold..
RANGE RES.17%
ROCKHOPPER17%
LLOYDS GRP.17%
SOUND ENERGY16%
SAREUM15%

Codes & Symbols

ISINGB00BWWYSP41
SymbolsVAL, LSE:VAL, VAL.L, VAL:LN, LON:VAL, XLON:VAL